Focal low-dose rate brachytherapy for the treatment of prostate cancer

References

• National Cancer Institute [homepage on the Internet]Previous version: SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations)US National Institutes of Health2012 [updated August 20, 2012]. Available from http://seer.cancer.gov/csr/1975_2009_pops09/index.htmlAccessed June 23, 2013
   Google Scholar
• HeidenreichABellmuntJBollaMEAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised diseaseEur Urol2011591617121056534
   PubMed Web of Science ®Google Scholar
• SylvesterJEGrimmPDWongJGalbreathRWMerrickGBlaskoJCFifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experienceInt J Radiat Oncol Biol Phys201181237638120864269
   PubMed Web of Science ®Google Scholar
• StockRGCesarettiJAStoneNNDisease-specific survival following the brachytherapy management of prostate cancerInt J Radiat Oncol Biol Phys200664381081616309852
   PubMed Web of Science ®Google Scholar
• ZelefskyMJKubanDALevyLBMulti-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantationInt J Radiat Oncol Biol Phys200767232733317084558
   PubMed Web of Science ®Google Scholar
• SandaMGDunnRLMichalskiJQuality of life and satisfaction with outcome among prostate-cancer survivorsN Engl J Med2008358121250126118354103
   PubMed Web of Science ®Google Scholar
• CossetJMWakilGPierratNCathelineauXMarchandVVallancienGPoster 710. Focal brachytherapy for prostate cancer: a pilot studyRadiotherapy and Oncology201199S283
   Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer CenterPhase II study assessing the potential for reduced toxicity using focal brachytherapy early stage, low volume in prostate cancerClinicalTrials.gov [website on the Internet]New York, NYMemorial Sloan-Kettering Cancer Center2011 [updated May 13, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01354951?term=focal+prostate&rank=5. NLM identifier: NCT01354951Accessed June 23, 2013
   Google Scholar
• NguyenPLChenMHZhangYUpdated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapyJ Urol201218841151115622901567
   PubMed Web of Science ®Google Scholar
• KamravaMChungMPKayodeOFocal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs conventional whole-gland treatmentBrachytherapy Epub2013211
   Web of Science ®Google Scholar
• MiralbellRMollàMRouzaudMHypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot studyInt J Radiat Oncol Biol Phys2010781505719910135
   PubMed Web of Science ®Google Scholar
• AluwiniSvan RooijPHoogemanMKirkelsWKolkman-DeurlooIKBangmaCStereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsRadiat Oncol201388423570391
   PubMed Web of Science ®Google Scholar
• SchickUPopowskiYNouetPHigh-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: hemi-irradiation of prostate cancerProstate201171121309131621308714
   PubMed Web of Science ®Google Scholar
• ZaiderMZelefskyMJLeeEKTreatment planning for prostate implants using magnetic-resonance spectroscopy imagingInt J Radiat Oncol Biol Phys20004741085109610863082
   PubMed Web of Science ®Google Scholar
• CooperbergMRLubeckDPMengMVMehtaSSCarrollPRThe changing face of low-risk prostate cancer: trends in clinical presentation and primary managementJ Clin Oncol200422112141214915169800
   PubMed Web of Science ®Google Scholar
• BottSRAhmedHUHindleyRGAbdul-RahmanAFreemanAEmbertonMThe index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancerBJU Int2010106111607161120553262
   PubMed Web of Science ®Google Scholar
• KaravitakisMWinklerMAbelPLivniNBeckleyIAhmedHUHistological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapyProstate Cancer Prostatic Dis2011141465220498680
   PubMed Web of Science ®Google Scholar
• MutoSYoshiiTSaitoKKamiyamaYIdeHHorieSFocal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancerJpn J Clin Oncol200838319219918281309
   PubMed Web of Science ®Google Scholar
• El FegounABBarretEPrapotnichDFocal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-upInt Braz J Urol2011372213219 discussion 220–22221557838
   PubMed Web of Science ®Google Scholar
• BahnDde Castro AbreuALGillISFocal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 yearsEur Urol2012621556322445223
   PubMed Web of Science ®Google Scholar
• LambertEHBolteKMassonPKatzAEFocal cryosurgery: encouraging health outcomes for unifocal prostate cancerUrology20076961117112017572198
   PubMed Web of Science ®Google Scholar
• OnikGVaughanDLotenfoeRDineenMBradyJ“Male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-upUrol Oncol200826550050518774463
   PubMed Web of Science ®Google Scholar
• KeyesMMillerSMoravanVPredictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patientsInt J Radiat Oncol Biol Phys20097341023103219111402
   PubMed Web of Science ®Google Scholar
• CrookJFleshnerNRobertsCPondGLong-term urinary sequelae following 125iodine prostate brachytherapyJ Urol2008179114114517997424
   PubMed Web of Science ®Google Scholar
• StoneNNStockRGLong-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 yearsUrology200769233834217320674
   PubMed Web of Science ®Google Scholar
• KeyesMMillerSMoravanVUrinary symptom fare in 712 125I prostate brachytherapy patients: long-term follow-upInt J Radiat Oncol Biol Phys200975364965519211199
   PubMed Web of Science ®Google Scholar
• KeyesMSpadingerILiuMRectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patientsBrachytherapy201211319920821763213
   PubMed Web of Science ®Google Scholar
• TranAWallnerKMerrickGRectal fistulas after prostate brachytherapyInt J Radiat Oncol Biol Phys200563115015416111583
   PubMed Web of Science ®Google Scholar
• CrookJBorgJEvansA10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patientsInt J Radiat Oncol Biol Phys20118051323132920675072
   PubMed Web of Science ®Google Scholar
• PollackAZagarsGKStarkschallGProstate cancer radiation dose response: results of the MD Anderson phase III randomized trialInt J Radiat Oncol Biol Phys20025351097110512128107
   PubMed Web of Science ®Google Scholar
• HalpernEJFrauscherFStrupSENazarianLNO’KanePGomellaLGProstate: high-frequency Doppler US imaging for cancer detectionRadiology20022251717712354987
   PubMed Web of Science ®Google Scholar
• MitterbergerMHorningerWPelzerAA prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detectionProstate200767141537154217705242
   PubMed Web of Science ®Google Scholar
• NewmanJSBreeRLRubinJMProstate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy siteRadiology1995195186907534429
   PubMed Web of Science ®Google Scholar
• RoyCBuyXLangHSaussineCJacqminDContrast enhanced color Doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedureJ Urol20031701697212796647
   PubMed Web of Science ®Google Scholar
• FeleppaEJFairWRLiuTThree-dimensional ultrasound analyses of the prostateMol Urol20004313313911062367
   PubMedGoogle Scholar
• FeleppaEJFairWRTsaiHProgress in two-dimensional and three-dimensional ultrasonic tissue-type imaging of the prostate based on spectrum analysis and nonlinear classifiersMol Urol19993330331010851337
   PubMedGoogle Scholar
• BraeckmanJAutierPSovianyCThe accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancersBJU Int2008102111560156518710457
   PubMed Web of Science ®Google Scholar
• HoytKCastanedaBZhangMTissue elasticity properties as biomarkers for prostate cancerCancer Biomark200844–521322518957712
   PubMed Web of Science ®Google Scholar
• NishidaSKinoshitaHMishimaTKurokawaHSakaidaNMatsudaTProstate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imagingInt J Urol201118965365821790792
   PubMed Web of Science ®Google Scholar
• PuechPPotironELemaitreLDynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimensUrology20097451094109919773038
   PubMed Web of Science ®Google Scholar
• VillersAPuechPMoutonDLeroyXBallereauCLemaitreLDynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findingsJ Urol20061766 Pt 12432243717085122
   PubMed Web of Science ®Google Scholar
• YamamuraJSalomonGBuchertRMR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (H) MR spectroscopy in comparison with histologyRadiol Res Pract2011201161685222091382
   PubMedGoogle Scholar
• ArumainayagamNAhmedHUMooreCMFreemanASohaibAKirkhamAA negative multi-parametric MRI can rule out up to 97% of clinically significant prostate cancerEur Urol Suppl20111026667
   Web of Science ®Google Scholar
• KobusTHambrockTHulsbergen-van de KaaCAIn vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coilEur Urol20116051074108021419565
   PubMed Web of Science ®Google Scholar
• DickinsonLAhmedHUAllenCMagnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meetingEur Urol201159447749421195536
   PubMed Web of Science ®Google Scholar
• BostwickDGMeiersIProstate biopsy and optimization of cancer yieldEur Urol200649341541716442209
   PubMed Web of Science ®Google Scholar
• BostwickDGQianJDrewnowskaKProstate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processingUrology20107561406141019942263
   PubMed Web of Science ®Google Scholar
• OnikGMiessauMBostwickDGThree-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer managementJ Clin Oncol200927264321432619652073
   PubMed Web of Science ®Google Scholar
• FalzaranoSMZhouMHernandezAVMoussaASJonesJSMagi-GalluzziCCan saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapyUrology201076368268720206973
   PubMed Web of Science ®Google Scholar
• SinnottMFalzaranoSMHernandezAVDiscrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapyProstate201272111179118622161896
   PubMed Web of Science ®Google Scholar
• HambrockTSomfordDMHoeksCMagnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigenJ Urol2010183252052720006859
   PubMed Web of Science ®Google Scholar
• AhmedHUHuYCarterTCharacterizing clinically significant prostate cancer using template prostate mapping biopsyJ Urol2011186245846421679984
   PubMed Web of Science ®Google Scholar
• HorningerWBergerAPRogatschHCharacteristics of prostate cancers detected at low PSA levelsProstate200458323223714743461
   PubMed Web of Science ®Google Scholar
• MastersonTAChengLMehanRMKochMOTumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancerJ Urol2011186250651021679993
   PubMed Web of Science ®Google Scholar
• OhoriMEasthamJAKohHKuroiwaKSlawinKMWheelerTMIs focal therapy reasonable in patients with early stage prostate cancer (CaP) – an analysis of radical prostatectomy (RP) specimensJ Urol2006Suppl 175507
   Web of Science ®Google Scholar
• AroraRKochMOEbleJNUlbrightTMLiLChengLHeterogeneity of Gleason grade in multifocal adenocarcinoma of the prostateCancer2004100112362236615160339
   PubMed Web of Science ®Google Scholar
• LangleySAhmedHUAl-QaisiehBReport of a consensus meeting on focal low dose rate brachytherapy for prostate cancerBJU Int2012109Suppl 171622239224
   PubMed Web of Science ®Google Scholar
• Urology Specialists, PCInternational Prostate Symptom Score (I-PSS)Middlebury, CT, USAUrology Specialists, PC2013 Available from: http://www.urospec.com/uro/Forms/ipss.pdfAccessed June 23, 2013
   Google Scholar
• SaibishkumarEPBorgJYeungICummins-HolderCLandonACrookJSequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancerInt J Radiat Oncol Biol Phys2009731616818823713
   PubMed Web of Science ®Google Scholar
• DavisBJHorwitzEMLeeWRAmerican Brachytherapy SocietyAmerican Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapyBrachytherapy201211161922265434
   PubMed Web of Science ®Google Scholar
• SalembierCLavagniniPNickersPGEC ESTRO PROBATE GroupTumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapyRadiother Oncol200783131017321620
   PubMed Web of Science ®Google Scholar
• BuyyounouskiMKHorwitzEMUzzoRGThe radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapyInt J Radiat Oncol Biol Phys20045951383139115275723
   PubMed Web of Science ®Google Scholar
• GillanCKirilovaALandonAYeungIPondGCrookJRadiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiographyInt J Radiat Oncol Biol Phys200665368869316626892
   PubMed Web of Science ®Google Scholar
• MerrickGSButlerWMWallnerKEThe importance of radiation doses to the penile bulb vs crura in the development of postbrachytherapy erectile dysfunctionInt J Radiat Oncol Biol Phys20025441055106212419431
   PubMed Web of Science ®Google Scholar
• BefortCAZelefskyMJScardinoPTBorrayoEGieslerRBKattanMWA measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale developmentClin Prostate Cancer20054210010816197610
   PubMedGoogle Scholar
• RosenRCRileyAWagnerGOsterlohIHKirkpatrickJMishraAThe international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology19974968228309187685
   PubMed Web of Science ®Google Scholar
• BarryMJFowlerFJJrO’LearyMPThe American Urological Association symptom index for benign prostatic hyperplasiaJ Urol19921485154915571279218
   PubMed Web of Science ®Google Scholar
• WeiJTDunnRLLitwinMSDevelopment and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate CancerUrology200056689990511113727
   PubMed Web of Science ®Google Scholar
• GroenvoldMKleeMCSprangersMAValidation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreementJ Clin Epidemiol19975044414509179103
   PubMed Web of Science ®Google Scholar
• van AndelGBottomleyAFossåSDAn international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancerEur J Cancer200844162418242418774706
   PubMed Web of Science ®Google Scholar
• RajputABMillerMADe LucaAFrequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancersJ Clin Pathol200760111238124317259299
   PubMed Web of Science ®Google Scholar
• MorganRBoxallABhattAEngrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancerClin Cancer Res20111751090109821364037
   PubMed Web of Science ®Google Scholar
• KimCKParkBKLeeHMKimSSKimEMRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancerAJR Am J Roentgenol200819051180118618430829
   PubMed Web of Science ®Google Scholar
• RouvièreOGirouinNGlasLProstate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRIEur Radiol2010201485519690866
   PubMed Web of Science ®Google Scholar
• ArumainayagamNKumaarSAhmedHUAccuracy of multi-parametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapyBJU Int2010106799199720230392
   PubMed Web of Science ®Google Scholar
• HaiderMAChungPSweetJDynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapyInt J Radiat Oncol Biol Phys200870242543017881141
   PubMed Web of Science ®Google Scholar
• De VisscherePJDe MeerleerGOFüttererJJVilleirsGMRole of MRI in follow-up after focal therapy for prostate carcinomaAJR Am J Roentgenol201019461427143320489080
   PubMed Web of Science ®Google Scholar
• AllenGWHowardARJarrardDFRitterMAManagement of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage optionCancer200711071405141617685384
   PubMed Web of Science ®Google Scholar
• NguyenPLD’AmicoAVLeeAKSuhWWPatient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literatureCancer200711071417142817694553
   PubMed Web of Science ®Google Scholar
• ChalasaniVMartinezCHLimDChinJSalvage HIFU for recurrent prostate cancer after radiotherapyProstate Cancer Prostatic Dis200912212412918852702
   PubMed Web of Science ®Google Scholar
• BoukaramCHannoun-LeviJMManagement of prostate cancer recurrence after definitive radiation therapyCancer Treat Rev420103629110020100637
   PubMed Web of Science ®Google Scholar
• TsivianMAbernMRPolascikTJEvolution of the concept of focal therapy for prostate cancerOncology (Williston Park)2013271646823461042
   PubMed Web of Science ®Google Scholar
• AhmedHUHindleyRGDickinsonLFocal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyLancet Oncol201213662263222512844
   PubMed Web of Science ®Google Scholar
• AhmedHUFreemanAKirkhamAFocal therapy for localized prostate cancer: a phase I/II trialJ Urol201118541246125421334018
   PubMed Web of Science ®Google Scholar
• Eastern Cooperative Oncology Group [homepage on the Internet]ECOG performance status2011 [updated July 27, 2006]. Available from: http://www.ecog.org/general/perf_stat.htmlAccessed June 23, 2013
   Google Scholar